All In Biotech

Free tool

FAERS Monitor: Iheezo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216227 or its brand name (Iheezo, Chloroprocaine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

108

Serious

4

4% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective55
  • underdose54
  • eye irritation21
  • eye pain20
  • ocular hyperaemia8
  • lacrimation increased7
  • ocular discomfort7
  • product temperature excursion issue7
  • conjunctival hyperaemia6
  • off label use5
  • vision blurred3
  • corneal abrasion2
  • eyelid margin crusting2
  • hypersensitivity2
  • conjunctival haemorrhage1

Reports by year received

View as table
YearReports
20242
202512
202694

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,051 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
conjunctival hyperaemiaSignal6328.4150.81,642
corneal abrasion2284.672.0317
product temperature excursion issueSignal7265.7129.71,589
underdoseSignal54144.2119.47,556
eyelid margin crusting2134.934.1149
ocular discomfortSignal7121.559.3720
eye irritationSignal2171.148.41,385
eye painSignal2069.146.51,277
conjunctival haemorrhage151.07.212
lacrimation increasedSignal745.122.0260
ocular hyperaemiaSignal832.816.9217
drug ineffectiveSignal558.16.8359
vision blurredSignal34.31.45
hypersensitivity22.10.50
off label use51.10.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.